Araris Biotech AG
Building tomorrow's antibody-drug conjugates (ADCs)
Building tomorrow's antibody-drug conjugates (ADCs)
Araris Biotech AG is a Switzerland-based startup founded in 2019, focusing on the development of antibody-drug conjugates (ADCs). The company's innovative linker technology allows for the attachment of various payloads to 'off the shelf' antibodies without the need for prior antibody engineering. This approach has the potential to revolutionize the field of biotechnology and healthcare, offering a more efficient and cost-effective solution for the creation of ADCs.
Araris Biotech AG's recent milestone includes a grant investment received on 28 April 2023 from Innosuisse, indicating confidence in the company's technological advancements and market potential. With its focus on building tomorrow's ADCs, Araris Biotech AG stands at the forefront of innovation in the biopharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
11 Apr 2023 |
| Series A | $24.00M | 8 |
|
04 Oct 2022 |
| Seed Round | Fr.15.20M | 7 |
|
22 Oct 2020 |
| Seed Round | Fr.2.50M | 3 |
|
20 Aug 2019 |
| Pre Seed Round | Fr.100.00K | 1 |
|
12 Jun 2019 |
No recent news or press coverage available for Araris Biotech AG.
We care about your data, and we'd love to use cookies make your experience better.
